Keio University

Japan Science and Technology Corporation

Massachusetts Eye and Ear Infirmary

Cornell Research Foundation Inc.

Japan Science and Technology Agency

Osaka University

Chugai Seiyaku Kabushiki Kaisha

Kyoto University

Ono Pharmaceutical Co., Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

Kringle Pharma Inc.

Central Institute for Experimental Animals

Advanced Industrial Science and Technology

Keiichi Fukuda

Purec Co., Ltd.

Hideyuki Okano

Masaya Nakamura

Albert Edge

Takuya Matsumoto

Shinya Yamanaka

Toshikazu Nakamura

Steven A Goldman

Kazuo Tsubota

Masato Fujioka

Kaoru Ogawa

Yohei Okada

Yoshiaki Toyama

Fumihiko Kisa

Makoto Hosoya

Masahiro Toda

Hiroyuki Miyoshi

Katsuhiko Mikoshiba

Hidehiro Mizusawa

Akihiko Sano

Jun Hirabayashi

Kiyoshi Ando

Shinsuke Yuasa

Ryota Tamura

Tatsuji Nomura

Yonehiro Kanemura

Shuichi Goto

Shigeto Shimmura

Akinori Tokunaga

Tatsuo Matsunaga

Wado Akamatsu

Masanori Sakaguchi

Takuya Shimazaki

Kazunobu Sawamoto

Kunio Mizutari

Satoru Ishibashi

Keigo Hanada

Uichi Koshimizu

Sho Kanzaki

Keijiro Sugimura

Jun Namiki

Kazuto Kobayashi

Erika Sasaki

Akiyoshi Kishino

Hiroshi Funakoshi

Tomofumi Tanaka

Hirotaka James Okano

Yo Mabuchi

Shinsuke Shibata

Tomoko Shindo

Koki Fujimori

Naoko Kuzumaki

Akio Iwanami

Kazuya Kitamura

Jun Kohyama

Keiko Nakao

Takahito Yazaki

Ryuichi Kanai

Kyoko Miura

Hayato Kaneda

Takeshi Kawase

James Hirotaka Okano

Yoshikuni Tanioka

Natsuki Matsushita

Miho Maeda

Takao Imai

Tetsu Yoshida

Masato Nakafuku

Seiji Shiozawa

Liang Zhang

Yumi Iyoku

Hironobu Okuno

Osahiko Tsuji

Hayato Naka

Masahiro Omoto

A culture medium for inducing a pluripotent stem cell into a differentiation-promoted pluripotent stem cell, the medium including a Glycogen synthase kinase 3β (GSK3β) inhibitor, a Bone morphogenic protein (BMP) signaling inhibitor, and a Transforming growth factor (TGF)-β inhibitor as active ingredients.

Differentiation-promoted pluripotent stem cell and use thereof

This invention relates to methods for treating hearing loss associated with loss of cochlear hair cells, e.g., caused by noise exposure, using certain gamma secretase inhibitors, in post-neonatal animals, e.g., adolescents and adults.

Treating hearing loss

A cell preparation for treating brain tumors used in combination with a prodrug that is converted to 5-fluorouracil by cytosine deaminase, wherein the cell preparation comprises neural stem cells derived from pluripotent stem cells having a cytosine deaminase gene and a uracil phosphoribosyltransferase gene is provided to establish new means for treating brain tumors.

Suicide gene therapeutic agent for brain tumors using pluripotent stem cell

Sample preparation system and method which enable electron microscope observation of a sample slice with simple structure and process are provided. The sample preparation system includes at least one of a plasma treatment apparatus and a sputtering apparatus, as well as a slice collecting apparatus. The plasma treatment apparatus is configured to feed a resin tape in a plasma irradiation area to irradiate the resin tape with plasma, thereby continuously hydrophilizing the resin tape. The sputtering apparatus is configured to feed the resin tape in a sputtering area to continuously perform sputtering on the resin tape, thereby imparting conductivity to the resin tape. The slice collecting apparatus is configured to serially collect slices cut out from a sample onto the resin tape having been subjected to plasma treatment or sputtering.

Sample preparation system and method for electron microscope observation, and tape feeding mechanism used for sample preparation

The present invention aims to obtain a method for quality evaluation of human mesenchymal stem cells, a method for isolation, selection and culture of human mesenchymal stem cells, a cell population of rapidly proliferating human mesenchymal stem cells, as well as monoclonal antibodies that specifically recognize rapidly proliferating human mesenchymal stem cells. From a cell population containing human mesenchymal stem cells, rapidly proliferating human mesenchymal stem cells are isolated, selected and cultured. The abundance ratio of cells expressing Ror2 or Fzd5 in the cell population thus isolated, selected and cultured is quantified to determine whether or not each cell population is acceptable.

Method for evaluating quality of human mesenchymal stem cell, and monoclonal antibody for use in said method

An object of the present invention is to provide novel apoptosis inhibitors and therapeutic agents for inner ear hearing impairment. As a pharmaceutical agent for this purpose, biguanide compounds represented by the following structural formula (I) or a rapamycin derivative represented by the following structural formula (II) as an active ingredient is provided: wherein Rto Rare each independently selected from a hydrogen atom, a halogen atom, or a Calkyl group, a Ccycloalkyl group, a Caryl group, a 5- or 6-membered heteroaryl group, or a 5- or 6-membered non-aromatic heterocyclic group, each of which may have a substituent selected from a halogen atom, a cyano group, a Calkyl group, a Calkoxy group, a Calkoxy carbonyl group, a Ccycloalkyl group, a Calkenyl group, a Calkynyl group, and a phenyl group; wherein Ris a Calkyl or a Calkynyl, Ris H, &#x2014;CH2-OH or &#x2014;CH&#x2014;CHOH, and X is &#x2550;O, (H, H) or (H, OH).

Therapeutic agents for inner ear hearing impairment

An object of the present invention is to provide novel apoptosis inhibitors and therapeutic agents for inner ear hearing impairment. As a pharmaceutical agent for this purpose, biguanide compounds represented by the following structural formula (I) or a rapamycin derivative represented by the following structural formula (II) as an active ingredient is provided: wherein Rto Rare each independently selected from a hydrogen atom, a halogen atom, or a Calkyl group, a Ccycloalkyl group, a Caryl group, a 5- or 6-membered heteroaryl group, or a 5- or 6-membered non-aromatic heterocyclic group, each of which may have a substituent selected from a halogen atom, a cyano group, a Calkyl group, a Calkoxy group, a Calkoxy carbonyl group, a Ccycloalkyl group, a Calkenyl group, a Calkynyl group, and a phenyl group; wherein Ris a Calkyl or a Calkynyl, Ris H, &#x2014;CH2-OH or &#x2014;CH&#x2014;CH&#x2014;OH, and X is &#x2550;O, (H, H) or (H, OH).

To produce and/or maintain na&#xef;ve pluripotent stem cells capable of highly expressing genes important for maintaining an undifferentiated state, which could not be achieved by known methods for producing pluripotent stem cells. The present invention can produce na&#xef;ve pluripotent stem cells capable of maintaining an undifferentiated state by introducing and allowing transient expression of six genes (Oct3/4, Klf4, c-Myc, Sox2, Nanog, and Klf2) among the so-called initializing factors, and further performing culturing in a medium containing LIF, an MEK inhibitor, a GSK3 inhibitor, a cAMP production promoter, a TGF-&#x3b2; inhibitor and a PKC inhibitor. Thus, the problem of the present invention can be solved.

Method for producing na&#xef;ve pluripotent stem cells

A method for differentiating a human differentiated cell-derived pluripotent stem cell into a neural stem cell is provided, which includes the steps of: making an embryoid body from the human differentiated cell-derived pluripotent stem cell; and culturing the embryoid body in a medium containing LIF to differentiate into a neural stem cell, so that, when the neural stem cell is allowed to differentiate in vitro after multiple subculturing of the neural stem cell, it differentiate mainly into neurons but substantially not into glial cells.

Culture method of embryoid bodies and/or neural stem cells derived from human differentiated cell-derived pluripotent stem cells

In order to provide a method for producing neural stem cells easily and quickly by inducing differentiation of somatic cells directly into neurospheres, dedifferentiation factors are introduced into somatic cells, which are then cultured in suspension in the presence of growth factors to produce the neurospheres, thereby allowing the neural stem cells to be produced quickly without establishing iPS cells.

Method for producing neurospheres

An object of the present invention to provide an agent for promoting the self-renewal of the neural stem cells and a method of using the same. ECF-L contained in a culture supernatant of endothelial progenitor cells derived from bone marrow has an effect of promoting the self-renewal of neural stem cells. Accordingly, ECF-L can be used as an ingredient of an agent for promoting the self-renewal of the neural stem cells, a pharmaceutical composition for growing the neural stem cells, and a pharmaceutical composition for treating a disease associated with neural dysfunction.

Self-renewal promoter for neural stem cells and method for using same

The present invention is a solid sustained-release formulation comprising an agent for inhibiting semaphorin 3A as an active ingredient, which comprises an agent for inhibiting semaphorin 3A and pharmaceutically acceptable hardly water-soluble solid substance, in which the carrier is silicone.

Preparation for treatment of spinal cord injury

To efficiently identify and select a clone from clones of induced pluripotent stem cells (iPS cell) having low tumor formation rate in vivo when allowed to differentiate and transplanted in a living body, iPS cells of the clones are induced to differentiate, undifferentiated cells among the cells after the induction of differentiation are detected, and a clone having the content of the undifferentiated cell below a control is selected.

Method for selecting clone of induced pluripotent stem cells

An object of the present invention is to provide a method for introducing a gene into an embryo for production of a human disease model primate animal using a non-human primate animal such as a marmoset. The present invention relates to a method for introducing a foreign gene into an early embryo of a non-human primate animal, which comprises placing early embryos of a non-human primate in a 0.2 M to 0.3 M sucrose solution, so as to increase the volume of the perivitelline spaces, and then injecting a viral vector containing a human foreign gene operably linked to a promoter into the perivitelline spaces of the early embryos.

Methods for introducing a human gene into a marmoset embryo for making a transgenic marmoset

Growing community of inventors

Tokyo, Japan

Hideyuki Okano